PURPOSE: to evaluate the cost of preventive mammographic screening in climacteric women, as compared to the cost of breast cancer treatment in more advanced stages. METHODS: one thousand and fourteen patients attended at the Climacteric outpatient service of the Gynecology Department, Federal University of São Paulo Paulista School of Medicine, were included in the study and submitted to mammographic test. All mammographic test's were analyzed by the same two physicians and classified according to the BI-RADS (Breast Imaging Reporting and Data System American College of Radiology) categories. The detected lesions were submitted to cytological and histological examination. RESULTS: the final diagnostic impression of the 1014 examinations, according to the classification of BI-RADS categories was: 1=261, 2=671, 3=59, 4=22 and 5=1. The invasive procedures were performed through a needle guided by ultrasound or stereotactic examinations: 33 fine-needle aspiration biopsies, 6 core biopsies guided by ultrasound and 20 core biopsies guided by stereotactic examination. Five cancer diagnoses were established. The total cost of this screening based on Brazilian procedure values was R76,593.79(25,534dollars).Therefore,thecostofthediagnosisofthefivecasesofcancerinthisscreeningwasR 15,318.75 (5,106 dollars) each. However, the average cost per patient screened was R75.53(25dollars).CONCLUSIONS:consideringthatthetotaltreatmentcostofonlyonecaseofbreastcancerinadvancedstageincludinghospitalcosts,surgery,chemotherapy,radiotherapyandhormonaltreatmentissimilartothecostof1,000mammographicscreeningsinclimactericwomen,itmaybeconcludedthatthecostoftheearlycancerdiagnosisprogramisworthitandshouldbeincludedinthepublichealthprogram,asawayofloweringthepublichealthexpense.OBJETIVOS:analisaroscustosdeumcicloderastreamentomamograˊficodoca^ncerdemamaempopulac\ca~ode1014mulheresnoclimateˊrioecompararcomoscustosdotratamentodoca^ncerdamamaemestaˊdiosmaisavanc\cados.MEˊTODOS:realizou−serastreamentoem1014mulheresatendidasemambulatoˊriodeClimateˊrio.TodasasmamografiasforamclassificadasdeacordocomascategoriasdoBI−RADSa¨(BreastImagingReportingandDataSystemAmericanCollegeofRadiology)easleso~esdetectadasforamsubmetidasaestudocitoloˊgicoouhistoloˊgico.AestimativadoscustosdosexameseprocedimentosrealizadosforamobtidosdaTabelaAMB92.RESULTADOS:aimpressa~odiagnoˊsticafinaldos1014exames,deacordocomaclassificac\ca~oemcategoriasdoBI−RADSa¨,foi:1=261;2=671;3=59;4=22;5=1.Osprocedimentosinvasivosrealizadostotalizaram33punc\co~escomagulhafinadirigidaporUSG,6bioˊpsiascomagulhagrossaorientadaporUSGe20bioˊpsiasorientadaspormamografia(estereotaxia).CombasenosvaloresdatabelaAMB92,foramnecessaˊriospararastrearediagnosticaressapopulac\ca~ocercadeR 76.000,00. Detectaram-se 5 cânceres de mama, ao custo aproximado de R15.318,75pordiagnoˊsticoemeˊdiadecustoporpacientedeR 75,53. CONCLUSÕES: considerando que o custo total do tratamento de um único caso de câncer de mama em estádio II ou mais pode atingir R$ 75.000,00, concluímos que os programas de rastreamento mamográfico podem ser incluídos entre as políticas de saúde.Universidade Federal de São Paulo (UNIFESP) Escola Paulista de Medicina Departamento de GinecologiaUNIFESP, EPM, Depto. de GinecologiaSciEL